Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate
a maintenance of treatment effect, equivalent to a delay of about two years in decline for
time to stand (TTSTAND) velocity, and confirm safety and tolerability benefits of vamorolone over the 2.5-year follow up period.
Long-term treatment with vamorolone resulted in significantly fewer corticosteroid-associated adverse events than reported in other clinical trials with other steroids.
Bemarituzumab is a Strong Strategic Fit With Amgen’s Innovative Oncology Portfolio
Amgen to Host Investor Call at 10:30 a.m. EST
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March 4, 2021 – Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, today announced an agreement under which Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. This acquisition adds Five Prime’s innovative pipeline to Amgen’s leading oncology portfolio.
Five Prime’s lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer. Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients
Memic Receives FDA De Novo Marketing Authorization For First-Ever Surgical Robotic System With Humanoid-Shaped Robotic Arms meddeviceonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from meddeviceonline.com Daily Mail and Mail on Sunday newspapers.
Parvovirus –B19 is an erythrotropic virus that selectively targets human red blood cells and their precursors.
29 In patients with SCD, this can lead to life-threatening anemia due to abrupt cessation of erythropoiesis. Features are new or worsening signs of anemia, with an acute drop in hemoglobin and reticulocytopenia in the absence of blood loss or sequestration. Urgent recognition and transfusion are necessary to prevent circulatory failure and death.
Splenic Complications
Streptococcus pneumoniae, Neisseria meningitides and
Salmonella species, leaving patients prone to life-threatening infections such as pneumonia, meningitis, osteomyelitis and sepsis. As a result, all febrile illnesses are considered medical emergencies until proven otherwise in infants and under-immunized children. Routine childhood vaccines are monitored and usually administered through primary care providers, with the addition of extended pneumococcal and meningococcal vaccines as standard of care. Th
Anxiety Often Rears Its Ugly Head pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.